
'No one has to watch someone they love suffer...': Bill Gates sees hope in the fight against Alzheimer's, and it's deeply personal, 5 years after his father's loss
Bill Gates sees hope in the fight against Alzheimer's: It's deeply personal; 5 years after his father's loss
Five years ago,
Bill Gates
experienced one of the most severe personal losses of his life: seeing his father, William H. Gates Sr., suffer through the heartless advance of Alzheimer's disease. In a stunning new essay on Gates Notes, the Microsoft co-founder vividly remembers,
'Watching my brilliant, loving father go downhill and disappear was a brutal experience.'
That experience has since driven his dedication to fighting this ruinous condition, not only through philanthropy, but through sheer technological and scientific push.
On the cutting edge of Alzheimer's research today, Bill Gates finds reasons for real hope. Following his visit to Indiana University's School of Medicine in 2024, he was invigorated by what he described as "the latest breakthrough": blood tests that could diagnose Alzheimer's years before signs of the disease show up. Combined with recently approved medications that slightly slow the march of the disease, Gates feels the world is moving closer to a day when no one will have to suffer the agony of losing a loved one. As he states,
'We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease.'
Bill Gates' fight against Alzheimer's is deeply personal
Alzheimer's is not only a health or numerical problem for Bill Gates—it's personal. More than 7 million Americans have Alzheimer's today, including almost 1 in 9 individuals aged 65 and older. And although treatment advances have seemed glacial, Gates's path has been a witness to love-driven perseverance. Spurred on by his father's pain and his call to action, Gates has emerged as one of the most vocal voices urging more money, improved tools, and increased urgency in Alzheimer's research.
Bill Gates on Alzheimer's: 'This simple blood test could change everything'
When Gates visited IU's School of Medicine, he discovered a revolution in the making for Alzheimer's care: blood tests to diagnose Alzheimer's. The tests quantify the amount and ratio of amyloid plaques and tau proteins—Alzheimer's signatures in the brain, years before full-blown symptoms emerge.
Early detection
: Researchers now recognise that Alzheimer's disease starts as much as 20 years before the development of clinical symptoms.
Scalable screening
: Rather than expensive PET scans or invasive cerebrospinal fluid analysis, a routine blood draw might become a standard part of checkups.
Proactive intervention
: Precocious diagnosis by blood tests might lead to treatments that halt intellectual decline before such damage to the brain is permanent.
Gates calls these advances a "game-changer"—not only for researchers, but also for families and caregivers who have felt helpless against the advancement of the disease.
Two FDA-approved drugs: A modest win with massive implications
Encouraging therapy isn't confined to diagnosis. In the past few months, the US Food and Drug Administration has licensed two novel Alzheimer's medications that have been demonstrated to moderately decelerate disease exacerbation. Though not cures, these medications constitute a significant turning point—from symptom treatment to addressing core pathology.
Proof of concept
: These approvals demonstrate proof of the amyloid hypothesis and lead to further innovation.
Strengthened pipeline
: Researchers and companies are increasingly likely to invest in comparable treatments, converting optimism into economic as well as health momentum.
Gates's enthusiasm is palpable:
'When combined with early diagnostics, I really am excited about the future of treating this disease.'
Bill Gates warns: Alzheimer's treatment progress at risk without public funding
Despite advances in science, Gates warns of an impending crisis: dwindling public funding. Over the past few months, budgets for the National Institutes of Health and connected research agencies have been trimmed, just when momentum is gaining steam.
He argues:
This is exactly when investment is most needed.
Government grants support large-scale clinical trials and early-stage science that private philanthropy cannot support on its own.
Scaling up biotech instruments such as blood tests and treatments necessitates infrastructures which only governments can develop and sustain.
'If we pull back now, all this progress could grind to a halt—and no private initiative can fill that gap,'
Gates writes.
Bill Gates sees a turning point: 'Alzheimer's no longer feels hopeless'
Over the past few years, Alzheimer's seemed like a black hole of despair—until now. Gates spotlights some of the reasons why the tide is turning:
Technological convergence
: Biomarker analysis enabled by AI, cheap genomic technologies, and wearable tech are improving detection accuracy and affordability.
Early diagnosis culture
: Screening for Alzheimer's might soon become part of normal healthcare, along with blood pressure and cholesterol tests.
Global advocacy
: An expanding group of caregivers, scientists, business leaders, and foundations making a difference.
Tangible progress
: From tests to therapies, the gradual trickle of breakthroughs is turning into a flood, exciting scientists as well as sufferers.
Gates's vision: A future free from Alzheimer's tragedy
For Bill Gates, fighting Alzheimer's is not about making headlines—it's about saving families the emotional anguish he suffered personally. He dreams of a world where:
Early detection technologies detect the disease years before symptoms arise.
Targeted treatments halt or slow the disease, maintaining quality of life.
Funding and public support fuel a massive research pipeline.
In his most passionate sentence, Gates pleads: 'We are on the cusp of turning the tide against dementia.' But he also warns that urgency must be followed by action—more money, more research, more courage in science.
Also read |
Jeff Bezos' Indian Creek property just got a $105 million neighbour; here's who bought the 'billionaire bunker' land
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Wire
an hour ago
- The Wire
Ottai Unveils Revolutionary AI-Powered Biosensor Set to Transform Chronic Disease Care
Groundbreaking Technology Empowers Patients to Take Control of Their Health HONG KONG, June 20, 2025 /PRNewswire/ -- Ottai, an Oxford-originated pioneer in AI digital health innovation, today announced the launch of its next-generation AI-powered wearable designed to revolutionize chronic disease management. This breakthrough device continuously monitors key biomarkers, leverages AI for real-time analysis and health log input, enhances patient-device interaction, and delivers personalized lifestyle recommendations. The Ottai biosensor disrupts the paradigm of traditional chronic disease monitoring—characterized by manual input, periodic lab tests, and reactive symptom management—by offering continuous monitoring paired with AI-driven automated and personalized inputs. It integrates deep learning algorithms to analyze vast amounts of real-time biomarker data and health logs, delivering actionable, tailored recommendations. The biosensor also supports intuitive voice-activated commands, allowing users to ask questions and add inputs while receiving real-time, personalized advice. "The Ottai biosensor represents a critical step toward scalable, patient-centric care," said Dr. Calvin Wang, Research Scientist at Ottai. "It represents a new era in healthcare—where we combine biosensing with AI to provide a dynamic and adaptive tool that evolves with patients' health needs and supports long-term disease management." The biosensor uses AI to power a smart health companion that supports users in real time: • Real-Time Biomarker Analysis: Track critical health metrics like glucose and detect episodes of hyperglycemia and hypoglycemia continuously. The device is validated against medical gold standards and CE-approved for its accuracy and reliability. • Personalized Recommendations: AI algorithms process data to suggest lifestyle, dietary, and activity adjustments, optimizing long-term health outcomes. • Voice-Activated Health Logs and Lifestyle Inquiries: Interact with the biosensor via voice commands to effortlessly log health data, dietary and lifestyle habits, personalized questions, receiving real-time, actionable responses. • AI-Driven Data Analysis: Advanced machine learning algorithms to analyze complex datasets, that offers users real-time insights into their health trends and risks. • Seamless Integration with Other Health Apps: Syncs with other health-tracking platforms such as Apple Health and smartwatches for users' best convenience. About Ottai Ottai is a leader in empowering individuals with actionable insights to prevent and manage chronic conditions. With a mission to make chronic disease management more accessible, personalized, and proactive, Ottai aims to revolutionize the healthcare landscape with advanced, user-friendly solutions. For more information and pricing and availability of Ottai sensors, visit or contact info@ , and connect with Ottai on Instagram , and Facebook . (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.). This is an auto-published feed from PTI with no editorial input from The Wire.
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
USFDA approves first HIV prevention shot needing only two doses a year
Even after decades of medical progress, HIV continues to infect thousands globally each day, according to estimates by the World Health Organization. In a major breakthrough, the US Food and Drug Administration (FDA) on Thursday approved lenacapavir, a long-acting injectable drug that offers near-complete protection against HIV with just two doses a year. Lenacapavir, developed by Gilead Sciences and marketed under the brand name Yeztugo, is the world's first twice-yearly HIV prevention shot. It could transform pre-exposure prophylaxis (PrEP) options, particularly for those who struggle with daily medication adherence due to stigma, access issues, or lifestyle factors. How does lenacapavir work? Lenacapavir is a capsid inhibitor, a class of drugs that blocks the protein shell (capsid) the HIV virus needs to replicate. Unlike oral PrEP pills that must be taken daily, lenacapavir is administered as an injection once every six months, providing a discreet and highly effective method of prevention. How effective is lenacapavir against HIV? In two large-scale clinical trials conducted by Gilead: The first trial involved over 2,000 women in sub-Saharan Africa and showed a 100 per cent reduction in HIV infections, outperforming the daily oral PrEP pill Truvada. The second trial, involving over 2,000 men and gender-diverse individuals, reported only two infections, yielding a 99.9 per cent prevention rate. 'This medicine only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention,' said Daniel O'Day, Chairman and CEO of Gilead Sciences. 'With the FDA approval of Yeztugo, we are one step closer to ending HIV.' Is lenacapavir safe? Clinical trials report that lenacapavir is well tolerated, with mild injection site reactions being the most common side effect. No serious safety concerns have emerged, making it a viable long-term option for prevention. Who stands to benefit the most? The twice-yearly dosing offers particular promise for: Young women LGBTQ+ individuals People in remote or underserved regions Public health experts say it will improve adherence and reduce infection rates in communities often left behind by daily-pill-based prevention strategies. When will lenacapavir be available outside the US? While the FDA has cleared the drug, approvals in other countries are still pending. Applications are under review in Europe, Australia, Canada, South Africa, Brazil, and Latin America. The World Health Organization is expected to release global guidance on July 14 during the International AIDS Conference in Kigali. How much will Yeztugo cost? Gilead has yet to announce the price of Yeztugo. However, analysts estimate that the US launch could cost up to $25,000 per year. Currently, lenacapavir is priced at $39,000 annually for HIV treatment use, though prices are expected to fall for prevention. Advocacy groups such as UNAIDS and Unitaid are calling for significant price reductions in low- and middle-income countries. Generic manufacturing is being explored, with estimates suggesting a potential price of $25–$46 per year if Gilead grants licences. What's the HIV situation in India? According to the National AIDS Control Organisation (NACO), an estimated 2.4 million people were living with HIV in India in 2021. That year, 41,970 AIDS-related deaths were recorded, underscoring the ongoing public health challenge.


Mint
an hour ago
- Mint
Iranian missile strikes near Microsoft office in Israel's Beer Sheva: Report
Livemint Updated 20 Jun 2025, 10:35 AM IST Smokes rises from a building of the Soroka hospital complex after it was hit by a missile fired from Iran in Beersheba, Israel, Thursday, June 19, 2025(AP) Iranian missile struck strikes near Microsoft office in Israel's Beer Sheva: Report